Highest-materiality recent filing
Acadia Q2 revenue up 16% to $308M; raises FY2026 guidance to $1.24-1.30B
DAYBUE net sales $125M (+30% YoY); NUPLAZID net sales $183M (+10% adj. YoY).
Shareholders approved amendment to 2024 Equity Incentive Plan, increasing authorized shares by 5,209,670.
Acadia Q1 revenue $268M (+10% YoY); DAYBUE sales $101M (+20%); reaffirms guidance
Total Q1 revenues $268M (+10% GAAP YoY, +11% adj); NUPLAZID $167M (+5% GAAP, +6% adj); DAYBUE $101M (+20%).
Acadia R&D Head Elizabeth Thompson plans retirement; stays through 2026 as consultant
Dr. Thompson will retire for personal reasons; remains as Head of R&D until successor appointed, then consultant through end of 2026.
Acadia Pharmaceuticals appoints Jonathan M. Poole to Board of Directors
Poole appointed effective March 3, 2026 as Class II director, term expiring at 2027 annual meeting.
Q4 2025 GAAP total revenue $284M; non-GAAP adjusted $298M (+16% YoY); FY25 GAAP $1.07B, non-GAAP $1.08B.
Acadia Pharmaceuticals reaffirms 2025 net sales guidance above $1B
Anticipates 2025 net sales will exceed $1 billion, consistent with prior guidance.
Acadia Q3 revenue $278.6M (+11% YoY); net income $71.8M; raises FY 2025 guidance
Q3 net product sales: NUPLAZID $177.5M (+12% YoY), DAYBUE $101.1M (+11% YoY).
Director Daniel B. Soland resigns from Acadia board and governance committee chair
Resignation effective October 30, 2025.
Acadia Q2 revenue $264.6M (+9% YoY); NUPLAZID guidance raised to $665-690M
Total revenue $264.6M, NUPLAZID $168.5M (+7%), DAYBUE $96.1M (+14%).
Federal Circuit affirms Acadia's NUPLAZID patent validity in MSN litigation
U.S. Court of Appeals affirmed District Court decision confirming validity of Acadia's '740 composition of matter patent for NUPLAZID (pimavanserin).
Acadia shareholders elect three Class III directors, approve say-on-pay, ratify EY auditor
Elected Catherine Owen Adams, Laura A. Brege, and Elizabeth A. Garofalo, M.D. as Class III directors; each received >129M votes for.
Acadia wins patent litigation for NUPLAZID; court rules for Acadia on infringement and validity
U.S. District Court for Delaware ruled in Acadia's favor in Pimavanserin II Cases regarding '721 formulation patent for NUPLAZID.
Acadia Q1 revenue +19% to $244.3M; net income $19M; ACP-101 results accelerated to Q4 2025
Total Q1 revenue $244.3M, up 19% YoY; NUPLAZID sales $159.7M (+23%), DAYBUE $84.6M (+11%)
Acadia Pharmaceuticals amends bylaws, tightens stockholder nomination and meeting rules
Quorum threshold changed from majority of outstanding shares to majority of voting power.
Acadia Q4 net income $143.7M; FY2024 revenue $957.8M (+32%); guides FY2025 rev $1.03-1.095B
FY2024 total net product sales $957.8M, up 32% YoY; NUPLAZID $609.4M (+11%), DAYBUE $348.4M (+97%).
Acadia sells Rare Pediatric Disease PRV for $150M, one third to partner Neuren
Closed sale of PRV for $150M on Dec 11, 2024, after HSR waiting period expired.
Acadia Pharma terminates COO Brendan Teehan without cause; CEO assumes duties
Brendan Teehan, EVP, COO and Head of Commercial, involuntarily terminated without Cause effective Nov 18, 2024.
Acadia Q3 total revenue $250.4M (+18% YoY); net income $32.8M vs year-ago loss
NUPLAZID sales $159.2M (+10% YoY); DAYBUE sales $91.2M (+36% YoY).
Acadia CEO Stephen R. Davis terminated Sept 23; Catherine Owen Adams appointed
Stephen R. Davis involuntarily terminated without cause as President and CEO effective Sept 23, 2024; resigns from board.
Acadia Q2 total revenue up 46% to $242M; net income $33.4M vs $1.1M last year
NUPLAZID net sales $157.4M (+11% YoY); DAYBUE net sales $84.6M (vs $23.2M YoY).
Acadia shareholders elect directors, approve 2024 equity plan at annual meeting
Julian C. Baker, Stephen R. Biggar, and Daniel B. Soland elected as Class II directors.
Acadia Q1 revenue $205.8M (+74% YoY), net income $16.6M vs loss year ago
NUPLAZID net sales $129.9M (+10% YoY); DAYBUE net sales $75.9M (vs $0 in Q1 2023)
Pimavanserin failed Phase 3 ADVANCE-2 trial for negative symptoms of schizophrenia; primary endpoint not met.
Acadia Pharma Q4 net income $45.8M; 2023 revenue $726.4M (+40%); FY2024 DAYBUE guide $370-420M
Q4 2023 net income $45.8M ($0.28 EPS) vs net loss $41.7M ($0.26 loss) in Q4 2022.
Acadia EVP, General Counsel Austin Kim departs; transition period
Austin D. Kim, Executive VP, General Counsel & Secretary, leaves Acadia to pursue other opportunities.
Acadia Pharma EVP R&D Doug Williamson to depart; search for replacement underway
Doug Williamson, MD, EVP Head of R&D, leaving Acadia to pursue other opportunities.
Acadia Q3 2023 record revenue $211.7M; DAYBUE launch strong at $66.9M, NUPLAZID grows
Q3 total revenue $211.7M; DAYBUE net sales $66.9M (first full quarter), NUPLAZID $144.8M, up from $130.7M YoY
Acadia Q2 net income $1.1M; DAYBUE launch strong with $23.2M sales; guides Q3 DAYBUE $45-55M
Q2 net income of $1.1M ($0.01/share) vs net loss of $34.0M in prior year; total product sales $165.2M.
Acadia expands trofinetide rights globally; Q2 DAYBUE net sales $21-23M
Acadia pays Neuren $100M upfront for ex-North American trofinetide rights and global NNZ-2591 rights in Rett/Fragile X.
Elected James M. Daly, Edmund P. Harrigan, and Adora Ndu as Class I directors (for votes: 108.2M, 126.2M, 131.6M).
Acadia Q1 net loss narrows to $43M; DAYBUE approved and launched for Rett syndrome
NUPLAZID net sales $118.5M, up 3% YoY; demand grew ~2%.
Acadia discloses $9.2M total exposure to failed Silicon Valley Bank
Approximately $1M in deposit accounts at SVB for daily cash needs as of March 10, 2023.
Acadia Pharma Q4 NUPLAZID sales $136.5M, full-year $517.2M; PDUFA for trofinetide March 12
Net sales $517.2M in 2022, up 7% YoY; Q4 sales $136.5M, up 4% YoY.
Acadia Q3 net sales $130.7M (-1% YoY), net loss widens; trofinetide PDUFA Mar 2023
Q3 net sales $130.7M (-1% YoY); net loss $27.2M ($0.17 loss/share) vs $14.5M loss a year ago.
President Srdjan R. Stankovic to retire Dec 31, 2022; will remain as consultant
Srdjan R. Stankovic notified Acadia of his retirement as President, effective Dec 31, 2022.
Acadia appoints Adora Ndu to board, increases size to nine directors
Board increased from 8 to 9 members; Adora Ndu, Pharm.D., J.D. appointed effective Oct 12, 2022.
Acadia Q2 NUPLAZID sales $134.6M (+17% YoY); NDA filed for trofinetide in Rett syndrome
Q2 net loss $34.0M ($0.21/share) vs $43.9M loss in Q2 2021; six-month loss $147.1M.
Acadia stockholders approve 6M share increase for equity plan, elect directors
Stockholders approved amendment to 2010 Equity Incentive Plan, increasing authorized shares by 6,000,000 (135.2M for, 6.6M against).
Acadia Q1 NUPLAZID sales $115.5M (+8% YoY); net loss widens to $113.1M on $60M Stoke payment
Q1 NUPLAZID net sales $115.5M (+8% vs $106.6M Q1 2021); net loss $113.1M ($0.70/sh) vs $66.4M loss in prior year.
Acadia grants retention RSUs to CEO, President, and General Counsel
CEO Stephen R. Davis receives 277,331 RSUs; President Srdjan R. Stankovic 144,695 RSUs; EVP Gen. Counsel Austin D. Kim 96,463 RSUs.
Acadia reports $484.1M 2021 net sales (+10% YoY); net loss narrows to $167.9M
Q4 2021 net product sales $130.8M (+8% YoY); full-year net sales $484.1M (+10% YoY).
Acadia plans Q1 2022 sNDA resubmission for pimavanserin in Alzheimer's disease psychosis
Resubmission targets Alzheimer's disease psychosis (ADP) instead of broader dementia-related psychosis.
Acadia names Mark Schneyer permanent CFO; previously interim CFO since Sept 2021
Mark Schneyer appointed EVP, CFO effective Dec 9, 2021; had served as interim CFO since Sept 2021.
Acadia reports positive Phase 3 trofinetide results in Rett syndrome; NDA plan mid-2022
Trofinetide met co-primary endpoints: RSBQ change -5.1 vs -1.7 (p=0.0175); CGI-I 3.5 vs 3.8 (p=0.003).
Acadia Pharma Q3 net loss narrows to $0.09/shr; NUPLAZID sales up 9% to $131.6M
Net loss per share of $0.09, improved from $0.54 loss in Q3 2020; revenue $131.6M (+9% YoY).
Acadia appoints Brendan Teehan as EVP, COO, Head of Commercial; two executives depart
Brendan Teehan promoted to EVP, Chief Operating Officer and Head of Commercial, effective immediately.
Acadia CFO Elena Ridloff resigns; CEO Davis named principal financial officer
Elena Ridloff resigned as EVP and CFO effective September 10, 2021.
2Q21 net sales $115.2M (+5% YoY); net loss $43.9M ($0.27/share) vs $42.1M loss in 2Q20.
On April 27, 2026, Elizabeth H.Z. Thompson, Ph.D., Head of Research and Development, informed Acadia Pharmaceuticals Inc. (the “Company”) of her planned retirement.
On November 18, 2024, Acadia Pharmaceuticals Inc. (the “Company”) agreed with Brendan Teehan, Executive Vice President, Chief Operating Officer and Head of Commercial that he would be involuntarily terminated without Cause (as such term is defined in the Company’s Management Severance Benefit Plan (the “Severance Plan”)) from his position, effective immediately.
Stephen R. Davis is departing the Company and will be succeeded by Catherine Owen Adams.
On September 20, 2024, the Board appointed Catherine Owen Adams, age 54, to serve as the Chief Executive Officer of the Company, including as the “principal executive officer” of the Company within the meaning of Rule 16a-1(f) under the Securities Exchange Act of 1934, as amended, effective as of the Transition Date.
On January 30, 2024, Acadia Pharmaceuticals Inc. (the “Company”) announced that Austin D. Kim, Executive Vice President, General Counsel and Secretary, will be leaving the Company to pursue other opportunities.
On October 27, 2022, Srdjan R. Stankovic, M.D., M.S.P.H., notified Acadia Pharmaceuticals Inc. (the “Company”) of his intention to retire as the Company’s President, effective December 31, 2022.
appointed Adora Ndu, Pharm.D., J.D. as a director to fill the newly created vacancy.
On December 9, 2021, the Board of Directors of Acadia Pharmaceuticals Inc. (the “Company”) appointed Mark C. Schneyer as Executive Vice President, Chief Financial Officer.
On November 1, 2021, the Board of Directors of Acadia Pharmaceuticals Inc. (the “Company”) appointed Brendan P. Teehan as Executive Vice President, Chief Operating Officer and Head of Commercial and as the Company’s principal operating officer.
Elena Ridloff gave notice on August 30, 2021 of her resignation as Executive Vice President and Chief Financial Officer of Acadia Pharmaceuticals Inc. (the “Company”), effective September 10, 2021.
On August 31, 2021, the Board of Directors of the Company (the “Board”) appointed Stephen Davis, the Company’s Chief Executive Officer, as the Company’s principal financial officer.
The Board also appointed Mark Schneyer as the Company’s interim Chief Financial Officer.
Max materiality 0.85 · Median 0.70 · Most common event earnings